DRNA Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals...

Stats
Šios dienos apimtis	5.54M
Vidutinė apimtis	3.03M
Rinkos kapitalizacija	0.00
EPS	$-0.220 ( 2021-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.989 (2.59%)

Insider Trading

Date	Person	Action	Amount	type
2021-12-28	Koppel Adam	Sell	3 080 237	Common Stock
2021-12-28	Koppel Adam	Sell	3 333	Restricted Stock Units
2021-12-28	Koppel Adam	Sell	25 000	Director Stock Option (Right to Buy)
2021-12-28	Koppel Adam	Sell	25 000	Director Stock Option (Right to Buy)
2021-12-28	Koppel Adam	Sell	25 000	Director Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 100 transactions
Buy: 12 087 \| Sell: 8 528 928

Tūris Koreliacija

Ilgas: 0.55 (weak)

Trumpas: 0.93 (very strong)

Signal:(82.281) Expect same movement, but be aware

Dicerna Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
ORTX	0.976
ASLN	0.972
ADMS	0.97
CSII	0.969
GRBK	0.962
WPRT	0.96
UNCY	0.959
NERV	0.959
NATI	0.958
NNOX	0.956

10 Labiausiai neigiamai susiję koreliacijos
CPTN	-0.96
AADI	-0.958
CARA	-0.957
STIM	-0.956
PRAA	-0.955
BRKL	-0.953
VEON	-0.948
PEBK	-0.947
TCPC	-0.947
MDRX	-0.946

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Dicerna Pharmaceuticals Koreliacija - Valiuta/Žaliavos

0.04
( neutral )

0.41
( neutral )

0.35
( neutral )

0.61
( weak )

0.65
( weak )

-0.05
( neutral )

Dicerna Pharmaceuticals Finansinės ataskaitos

Annual	2020
Pajamos:	$164.31M
Bruto pelnas:	$164.31M (100.00 %)
EPS:	$-1.520

FY	2020
Pajamos:	$164.31M
Bruto pelnas:	$164.31M (100.00 %)
EPS:	$-1.520

FY	2019
Pajamos:	$23.90M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.760

FY	2018
Pajamos:	$6.18M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.600

Financial Reports:

No articles found.

Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.